{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:28:52Z","timestamp":1793640532679,"version":"4.5.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100020388","name":"Invitae Corp","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020388","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41391-025-01013-3","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T17:35:08Z","timestamp":1758562508000},"page":"346-352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5767-0548","authenticated-orcid":false,"given":"Neal D.","family":"Shore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2531-7587","authenticated-orcid":false,"given":"Christopher M.","family":"Pieczonka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Heron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukaram","family":"Gazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Cahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence H.","family":"Belkoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron D.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Mazzarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Veys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9054-6899","authenticated-orcid":false,"given":"David","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Bevan-Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Engelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Dato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3419-4723","authenticated-orcid":false,"given":"David R.","family":"Wise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Kay","family":"Hardwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry W.","family":"Aradhya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4227-3675","authenticated-orcid":false,"given":"Brandie","family":"Heald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Nussbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0849-7018","authenticated-orcid":false,"given":"Kathryn E.","family":"Hatchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Bucknor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9205-3756","authenticated-orcid":false,"given":"Edward D.","family":"Esplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"1013_CR1","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1200\/JCO.20.00046","volume":"38","author":"VN Giri","year":"2020","unstructured":"Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, et al. Implementation of germline testing for prostate cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020;38:2798\u2013811.","journal-title":"J Clin Oncol"},{"key":"1013_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/JU.0000000000002757","volume":"208","author":"JA Eastham","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, et al. Clinically localized prostate cancer: AUA\/ASTRO Guideline, Part I: introduction, risk assessment, staging, and risk-based management. J Urol. 2022;208:10\u201318.","journal-title":"J Urol"},{"key":"1013_CR3","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. Prostate cancer, version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2023;21:1067\u201396.","journal-title":"J Natl Compr Cancer Netw"},{"key":"1013_CR4","doi-asserted-by":"publisher","unstructured":"Tuffaha H, Edmunds K, Fairbairn D, Roberts MJ, Chambers S, Smith DP, et al. Guidelines for genetic testing in prostate cancer: a scoping review. Prostate Cancer Prostatic Dis. 2023. https:\/\/doi.org\/10.1038\/s41391-023-00676-0.","DOI":"10.1038\/s41391-023-00676-0"},{"key":"1013_CR5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.euo.2023.07.008","volume":"6","author":"N Shore","year":"2023","unstructured":"Shore N, Gazi M, Pieczonka C, Heron S, Modh R, Cahn D, et al. Efficacy of National Comprehensive Cancer Network Guidelines in identifying pathogenic germline variants among unselected patients with prostate cancer: the PROCLAIM trial. Eur Urol Oncol. 2023;6:477\u201383.","journal-title":"Eur Urol Oncol"},{"key":"1013_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760","volume":"5","author":"P Nicolosi","year":"2019","unstructured":"Nicolosi P, Ledet E, Yang S, Michalski S, Freschi B, O\u2019Leary E, et al. Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines. JAMA Oncol. 2019;5:523\u20138.","journal-title":"JAMA Oncol"},{"key":"1013_CR7","first-page":"360","volume":"72","author":"VN Giri","year":"2022","unstructured":"Giri VN, Morgan TM, Morris DS, Berchuck JE, Hyatt C, Taplin M-E. Genetic testing in prostate cancer management: considerations informing primary care. CA Cancer J Clin. 2022;72:360\u201371.","journal-title":"CA Cancer J Clin"},{"key":"1013_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00282-8","volume":"6","author":"A Finch","year":"2022","unstructured":"Finch A, Clark R, Vesprini D, Lorentz J, Kim RH, Thain E, et al. An appraisal of genetic testing for prostate cancer susceptibility. npj Precis Oncol. 2022;6:43.","journal-title":"npj Precis Oncol"},{"key":"1013_CR9","doi-asserted-by":"crossref","unstructured":"Shore N, Pieczonka C, Heron S, Gazi M, Cahn D, Belkoff LH, et al. Clinician-reported management recommendations in response to universal germline genetic testing in patients with prostate cancer. J Urol. 2024;212:832\u201343.","DOI":"10.1097\/JU.0000000000004190"},{"key":"1013_CR10","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/pros.23535","volume":"78","author":"VN Giri","year":"2018","unstructured":"Giri VN, Obeid E, Hegarty SE, Gross L, Bealin L, Hyatt C, et al. Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling. Prostate. 2018;78:879\u201388.","journal-title":"Prostate"},{"key":"1013_CR11","doi-asserted-by":"publisher","unstructured":"Leader AE, Mercado J, Klein A, Hyatt C, Gross L, Brandt R, et al. Insight into how patients with prostate cancer interpret and communicate genetic test results: implications for families. J Community Genet. 2022. https:\/\/doi.org\/10.1007\/s12687-022-00603-1.","DOI":"10.1007\/s12687-022-00603-1"},{"key":"1013_CR12","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jmoldx.2015.04.009","volume":"17","author":"SE Lincoln","year":"2015","unstructured":"Lincoln SE, Kobayashi Y, Anderson MJ, Yang S, Desmond AJ, Mills MA, et al. A systematic comparison of traditional and multigene panel testing for hereditary breast and ovarian cancer genes in more than 1000 patients. J Mol Diagn. 2015;17:533\u201344.","journal-title":"J Mol Diagn"},{"key":"1013_CR13","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/gim.2017.37","volume":"19","author":"K Nykamp","year":"2017","unstructured":"Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho Y-Y, et al. Sherloc: a comprehensive refinement of the ACMG\u2013AMP variant classification criteria. Genet Med. 2017;19:1105\u201317.","journal-title":"Genet Med"},{"key":"1013_CR14","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1200\/OP.20.00431","volume":"16","author":"BM Szymaniak","year":"2020","unstructured":"Szymaniak BM, Facchini LA, Giri VN, Antonarakis ES, Beer TM, Carlo MI, et al. Practical considerations and challenges for germline genetic testing in patients with prostate cancer: recommendations from the Germline Genetics Working Group of the PCCTC. JCO Oncol Pract. 2020;16:811\u20139.","journal-title":"JCO Oncol Pract"},{"key":"1013_CR15","doi-asserted-by":"publisher","first-page":"107800","DOI":"10.1016\/j.pec.2023.107800","volume":"114","author":"C Harrison","year":"2023","unstructured":"Harrison C, Bartley N, Jacobs C, Best M, Vatter S, Meiser B, et al. Family communication and results disclosure after germline sequencing: a mixed methods study. Patient Educ Couns. 2023;114:107800.","journal-title":"Patient Educ Couns"},{"key":"1013_CR16","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/pros.23959","volume":"80","author":"S Greenberg","year":"2020","unstructured":"Greenberg S, Slager S, Neil BO, Cooney K, Maughan B, Stopa N, et al. What men want: Qualitative analysis of what men with prostate cancer (PCa) want to learn regarding genetic referral, counseling, and testing. Prostate. 2020;80:441\u201350.","journal-title":"Prostate"},{"key":"1013_CR17","first-page":"100212","volume":"25","author":"S Loeb","year":"2020","unstructured":"Loeb S, Byrne N, Walter D, Makarov DV, Wise DR, Becker D, et al. Knowledge and practice regarding prostate cancer germline testing among urologists: gaps to address for optimal implementation*,**. Cancer Treat Res Commun. 2020;25:100212","journal-title":"Cancer Treat Res Commun"},{"key":"1013_CR18","first-page":"e510","volume":"211","author":"JL Roberts","year":"2024","unstructured":"Roberts JL, Wang L, Rose B, Siebert T, Madlensky L, Nielsen SM, et al. Germline genetic testing for prostate cancer: ordering trends in the era of expanded hereditary cancer screening recommendations. Urol Oncol. 2024;211:e510.","journal-title":"Urol Oncol"},{"key":"1013_CR19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s12687-022-00600-4","volume":"13","author":"D Gould","year":"2022","unstructured":"Gould D, Walker R, Makari-Judson G, Seven M. Experiences of individuals with a variant of uncertain significance on genetic testing for hereditary cancer risks: a mixed method systematic review. J Community Genet. 2022;13:371\u20139.","journal-title":"J Community Genet"},{"key":"1013_CR20","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.euf.2022.03.018","volume":"8","author":"P Nicolosi","year":"2022","unstructured":"Nicolosi P, Heald B, Esplin ED. What is a variant of uncertain significance in genetic testing? Eur Urol Focus. 2022;8:654\u20136.","journal-title":"Eur Urol Focus"},{"key":"1013_CR21","doi-asserted-by":"publisher","first-page":"368","DOI":"10.5694\/mja2.51906","volume":"218","author":"DL De Silva","year":"2023","unstructured":"De Silva DL, Stafford L, Skandarajah AR, Sinclair M, Devereux L, Hogg K, et al. Universal genetic testing for women with newly diagnosed breast cancer in the context of multidisciplinary team care. Med J Aust. 2023;218:368\u201373.","journal-title":"Med J Aust"},{"key":"1013_CR22","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/jgc4.1687","volume":"32","author":"A L\u00f3pez-Fern\u00e1ndez","year":"2023","unstructured":"L\u00f3pez-Fern\u00e1ndez A, Villacampa G, Salinas M, Grau E, Darder E, Carrasco E, et al. Role of psychological background in cancer susceptibility genetic testing distress: It is not only about a positive result. J Genet Couns. 2023;32:778\u201387.","journal-title":"J Genet Couns"},{"key":"1013_CR23","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/cncr.33357","volume":"127","author":"JO Culver","year":"2021","unstructured":"Culver JO, Ricker CN, Bonner J, Kidd J, Sturgeon D, Hodan R, et al. Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients. Cancer. 2021;127:1275\u201385.","journal-title":"Cancer"},{"key":"1013_CR24","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1016\/j.gim.2022.08.023","volume":"24","author":"JC Tiner","year":"2022","unstructured":"Tiner JC, Mechanic LE, Gallicchio L, Gillanders EM, Helzlsouer KJ. Awareness and use of genetic testing: an analysis of the Health Information National Trends Survey 2020. Genet Med. 2022;24:2526\u201334.","journal-title":"Genet Med"},{"key":"1013_CR25","doi-asserted-by":"publisher","unstructured":"Liu YL, Maio A, Kemel Y, Salo-Mullen EE, Sheehan M, Tejada PR, et al. Disparities in cancer genetics care by race\/ethnicity among pan-cancer patients with pathogenic germline variants. Cancer. 2022. https:\/\/doi.org\/10.1002\/cncr.34434.","DOI":"10.1002\/cncr.34434"},{"key":"1013_CR26","first-page":"184","volume":"40","author":"VN Giri","year":"2022","unstructured":"Giri VN, Gross L, Cheng HH, Russo J, Paller CJ, Johnson JM, et al. Virtual genetics board for enhancing knowledge and practice of prostate cancer genetic testing: the ENGAGEMENT study. J Clin Orthod. 2022;40:184.","journal-title":"J Clin Orthod"},{"key":"1013_CR27","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/ajmg.c.31602","volume":"178","author":"K Stoll","year":"2018","unstructured":"Stoll K, Kubendran S, Cohen SA. The past, present and future of service delivery in genetic counseling: Keeping up in the era of precision medicine. Am J Med Genet C Semin Med Genet. 2018;178:24\u201337.","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"1013_CR28","doi-asserted-by":"crossref","unstructured":"Breen KE, Symecko H, Spielman K, Gebert R, Shah IH, Pundock S, et al. Clinical impact of a rapid genetic testing model for advanced prostate cancer patients. J Urol. 2023;209:918\u201327.","DOI":"10.1097\/JU.0000000000003186"},{"key":"1013_CR29","doi-asserted-by":"crossref","unstructured":"Abusamra SM, Solorzano MA, Luke M, Quarles J, Jacobs MF, Das S, et al. Satisfaction with clinician-led germline genetic counseling in patients with prostate cancer. J Urol. 2022;208:1007\u201317.","DOI":"10.1097\/JU.0000000000002865"},{"key":"1013_CR30","doi-asserted-by":"crossref","unstructured":"Scheinberg T, Goodwin A, Ip E, Linton A, Mak B, Smith DP, et al. Evaluation of a mainstream model of genetic testing for men with prostate cancer. JCO Oncol Pract. 2021;17:e204\u201316.","DOI":"10.1200\/OP.20.00399"},{"key":"1013_CR31","doi-asserted-by":"publisher","first-page":"106821","DOI":"10.1016\/j.cct.2022.106821","volume":"119","author":"S Loeb","year":"2022","unstructured":"Loeb S, Cheng HH, Leader A, Gross L, Nolasco TS, Byrne N, et al. Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): a randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing. Contemp Clin Trials. 2022;119:106821.","journal-title":"Contemp Clin Trials"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01013-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01013-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01013-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T02:42:26Z","timestamp":1779331346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01013-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1013"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-01013-3","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"assertion":[{"value":"19 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval for PROCLAIM was approved by WCG IRB (Puyallup, WA; protocol 20191596). All patients provided informed consent to have their de-identified data used in this study. This study was performed in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NS is a consultant or advisor for AbbVie, Amgen, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Boston Scientific, Clovis Oncology, Cold Genesys, Dendreon, EMD Serono, Merck, Exact Imaging, Exact Sciences, FerGene, Foundation Medicine, GConcology, Genentech, GenesisCare, Genomic Health, Guardant Health, Invitae, Janssen, MDxHealth, Merck, Moivant, Myriad Genetics, Nymox, Pacific Edge, Phosphorus, Pfizer, Propella, Sanofi Genzyme, Sesen Bio, Tolmar, and UroGen Pharma. CMP has received research funding from Astellas Pharma, AstraZeneca, Bayer, Dendreon, Eli Lilly, Invitae, Janssen, Merck, Myovant Sciences, Myriad Genetics, Pfizer, and Veru, and is a consultant for Astellas Pharma, AstraZeneca, Bayer, Dendreon, Foundation Medicine, Janssen, Large Urology Group Practice Association, Merck, Myovant Sciences, Pfizer, Sun, and UroGPO. DJC is a consultant for Janssen and AstraZeneca. LHB is a consultant for Marius Pharmaceuticals. ADB is a speaker for Astellas Pharma, Janssen, Myovant Sciences, and Pfizer. BM is a consultant for NeoTract\/Teleflex, Calyxo, MagForce USA, and UroDev Medical, and is Medical Director and an equity holder for Convergent Genomics. DM is a consultant for Astellas Pharma, AstraZeneca, Clovis Oncology, Decipher, Janssen, and Myriad Genetics. AE is a consultant for Myriad Genetics and an investigator for Palette Life Sciences. PD is a speaker for Astellas Pharma, Bayer, Dendreon, Exact Imaging, Janssen, Myovant, and Pfizer; and a consultant for Dendreon, Exact Imaging, and Myovant. DRW is a consultant for Foundation Medicine, Janssen, Labcorp, Leap Therapeutics, Myovant, and Pfizer. KWA, BH, KEH, and RLN were employees of Invitae Corp., now part of Labcorp. BB, EDE, and SMN are current employees of Labcorp. EDE is an advisor and stockholder of Taproot Health, Exir Bio, and ROMTech.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}